The first half of 2025 has been marked by a surge in strategic activity across the global healthcare, life sciences, and ...

Telehealth partners for Eli Lilly (LLY) continue to sell compounded GLP-1 weight-loss drugs despite an agreement with the pharma giant to end copycat sales after the FDA ended a years-long ...

The company is headquartered in London, UK with labs in Cambridge, UK. In January 2025, Alchemab announced an agreement with Eli Lilly and Company.

Lilly has also bet on monoclonal antibodies to address the neurodegenerative condition, amyotrophic lateral sclerosis. It has tapped London-based Alchemab Therapeutics for the latter’s monoclonal ...

Alchemab will develop the therapy through Phase 1 clinical trials, then Lilly will continue through the next steps and commercialization, as part of a deal that’s worth up to $415 million and builds ...

The collaboration began in July 2017 with a five-year agreement, where Lilly pledged up to $52m for life science research. Recently, Alchemab signed a licensing agreement valued at up to $415m with ...

Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and ...

Deals: Merck Animal Health and Kansas announced a $895 million investment in manufacturing as well as research and development facilities in De Soto. Eli Lil­ly is set to pay up to $415 million in an ...

Alchemab will take the programme through early Phase 1 clinical trials after which Lilly will lead all further development and commercialisation. Alchemab's platform uses state-of-the-art machine ...

Alchemab Therapeutics (Alchemab), the next generation biopharmaceutical company which uses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies from ...